PFIZER INC.

These results are supplied for informational purposes only.
Prescribing decisions should be made based on the approved package insert.

PROPRIETARY DRUG NAME® / GENERIC DRUG NAME:
Refacto AF® / Moroctocog alfa

PROTOCOL NO.: 3082A-101342 (B1831044)

PROTOCOL TITLE:

A Multicenter Study to Describe the Immunogenic Epitope(s) of FVIII in Previously Treated Patients With Congenital Hemophilia A who Develop Factor VIII Inhibitors While Receiving FVIII Infusion Therapy

EudraCT Number:

2004-000219-24

Study Centers:

Data not available.

Study Initiation and Final Completion Dates:

Data not available. This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.

Phase of Development:

Phase 4

Study Objective:

Data not available.

METHODS

Data not available.

RESULTS

Subject Disposition and Demography:

Data not available.

Efficacy Results:

Data not available.

Safety Results:

Data not available.

CONCLUSIONS:

Data not available.

This study was cancelled prior to enrollment of any study subjects and therefore no data were collected.